George C. Clark - 23 Nov 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role
VP, Chief Accounting Officer
Signature
/s/ George C. Clark
Issuer symbol
N/A
Transactions as of
23 Nov 2021
Net transactions value
-$205,761
Form type
4
Filing time
26 Nov 2021, 15:26:46 UTC
Previous filing
13 Aug 2021
Next filing
22 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $62,084 +1,915 +34% $32.42* 7,473 23 Nov 2021 Direct
transaction BHVN Common Shares Options Exercise $0 +5,000 +67% $0.000000 12,473 26 Nov 2021 Direct
transaction BHVN Common Shares Tax liability $267,845 -2,318 -19% $115.55* 10,155 26 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Employee Stock Option (right to buy) Options Exercise $0 -1,915 -29% $0.000000 4,795 23 Nov 2021 Common Shares 1,915 $32.42 Direct F2
transaction BHVN Restricted Share Unit Award Options Exercise $0 -5,000 -25% $0.000000 15,000 26 Nov 2021 Common Shares 5,000 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F2 The shares underlying this option vest in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the reporting person's continued service with the issuer at each vesting date.
F3 Each restricted share unit represents the contingent right to receive one common share of the issuer.
F4 The reporting person was granted 20,000 restricted share units on May 7, 2021, vesting in four equal installments on May 7, 2021, 2022, 2023 and 2024 subject to the reporting person's continued service with the issuer at each vesting date.
F5 Not applicable.